AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11009150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron‐folate supplements (36 g iron and 5 mg folate)
Number of subjects: 0
Study 8774567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (50 mg twice daily for 10 days, 4 cycles)
Number of subjects: 339
Study 8774567 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous chemotherapy (etoposide and vincristine or cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 339
Study 8774567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 339
Study 8774567 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study 1321543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 0
Study 1321543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.5 mg
Number of subjects: 0
Study 1321543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31443887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga classes for 3 months
Number of subjects: 40
Study 31443887 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) classes for 3 months
Number of subjects: 40
Study 27840322 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum‐chromium EES
Number of subjects: 2980
Study 27840322 — intervention group
Group type: COMPARATOR
Intervention: Cobalt‐chromium EES
Number of subjects: 2980
Study 25465809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25-50mg daily)
Number of subjects: 17
Study 25465809 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25mg daily)
Number of subjects: 17
Study 24388403 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex motor imagery (MI)
Number of subjects: 0
Study 24388403 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex MI by experienced pianists
Number of subjects: 0
Study 24388403 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex MI
Number of subjects: 0
Study 24388403 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar actions
Number of subjects: 0
Study 22435991 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-augmented diode laser treatment (ICG+DL)
Number of subjects: 31
Study 22435991 — intervention group
Group type: COMPARATOR
Intervention: Flashlamp-pumped pulsed dye laser (FPDL)
Number of subjects: 31
Study 20159133 — intervention group
Group type: EXPERIMENTAL
Intervention: Able-bodied participants
Number of subjects: 31
Study 20159133 — intervention group
Group type: COMPARATOR
Intervention: Participants with poliomyelitis
Number of subjects: 31
Study 20159133 — intervention group
Group type: EXPERIMENTAL
Intervention: Able-bodied participants and participants with poliomyelitis
Number of subjects: 31
Study 17217359 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of 400 microgram oral misoprostol
Number of subjects: 300
Study 17217359 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 400 microgram oral misoprostol
Number of subjects: 300
Study 15794383 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]PK11195 uptake in NAWM
Number of subjects: 30
Study 15794383 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]PK11195 uptake in T2-lesions
Number of subjects: 30
Study 15794383 — intervention group
Group type: COMPARATOR
Intervention: Brain atrophy in MS patients
Number of subjects: 30
Study 15794383 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of brain atrophy
Number of subjects: 30
Study 12499889 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA withdrawal
Number of subjects: 187
Study 12499889 — intervention group
Group type: COMPARATOR
Intervention: CsA continuation
Number of subjects: 187
Study 9462602 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop arbutamine stress echocardiography
Number of subjects: 1070
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg and 40 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg and 8 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg and 10 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg and 10 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 2 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER 2.5 mg
Number of subjects: 0
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 8575118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 2213283 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-based therapy
Number of subjects: 0
Study 2213283 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors or calcium channel blockers
Number of subjects: 0
Study 420999 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey-scale ultrasonography
Number of subjects: 212
Study 420999 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 212
Study 31584783 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamedis Eczema Therapy Cream (test product)
Number of subjects: 39
Study 31584783 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (identical test product without botanical combination)
Number of subjects: 39
Study 28566590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for men, 15 mg/day for women)
Number of subjects: 58
Study 28566590 — intervention group
Group type: COMPARATOR
Intervention: Metformin (750 mg/day)
Number of subjects: 58
Study 26272500 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training at ventilatory threshold (CTVT)
Number of subjects: 35
Study 26272500 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (IT)
Number of subjects: 35
Study 26272500 — intervention group
Group type: COMPARATOR
Intervention: Continuous training at high intensity (CTHI)
Number of subjects: 35
Study 26272500 — intervention group
Group type: EXPERIMENTAL
Intervention: All training types (CTHI, CTVT, IT)
Number of subjects: 35
Study 26272500 — intervention group
Group type: EXPERIMENTAL
Intervention: End-exercise vigour
Number of subjects: 35
Study 24105252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate 10 mg (reference)
Number of subjects: 26
Study 24105252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine salicylate 9.64 mg (test)
Number of subjects: 26
Study 24105252 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both formulations
Number of subjects: 26
Study 21660896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall training
Number of subjects: 36
Study 21660896 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-associate learning
Number of subjects: 36
Study 21660896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition training
Number of subjects: 36
Study 21660896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 19487926 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine eyedrops
Number of subjects: 50500
Study 16730270 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010
Study 16730270 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010
Study 15248845 — intervention group
Group type: EXPERIMENTAL
Intervention: Special care group (educational advice on allergen exposure reduction)
Number of subjects: 443
Study 15248845 — intervention group
Group type: EXPERIMENTAL
Intervention: Special care group
Number of subjects: 443
Study 15248845 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 443
Study 11520524 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drugs (diuretics or b-blockers)
Number of subjects: 6614
Study 11520524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 6614
Study 11520524 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 6614
Study 9291168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.15-0.2 g/kg body weight, administered monthly for 2 years
Number of subjects: 148
Study 9291168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 9291168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 148
Study 8326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Number of subjects: 48
Study 8326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Number of subjects: 48
Study 8326293 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Simvastatin and Pravastatin)
Number of subjects: 48
Study 8326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 48
Study 8326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 48
Study 3732227 — intervention group
Group type: EXPERIMENTAL
Intervention: CO measurement demonstration at the beginning of treatment
Number of subjects: 0
Study 3732227 — intervention group
Group type: COMPARATOR
Intervention: CO measurement demonstration at the end of treatment (prior to self-reports)
Number of subjects: 0
Study 3732227 — intervention group
Group type: COMPARATOR
Intervention: CO measurement demonstration at the end of treatment (subsequent to self-reports)
Number of subjects: 0
Study 31030644 — intervention group
Group type: EXPERIMENTAL
Intervention: non-linear pedagogy
Number of subjects: 22
Study 31030644 — intervention group
Group type: COMPARATOR
Intervention: linear pedagogy
Number of subjects: 22
Study 30257956 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous fecal microbiota transplantation (auto‐FMT)
Number of subjects: 25
Study 30257956 — intervention group
Group type: COMPARATOR
Intervention: no intervention (control)
Number of subjects: 25
Study 28223082 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 74
Study 28223082 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy of Cognitively Impaired Older Adults (ST‐CI)
Number of subjects: 74
Study 28223082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PATH and ST‐CI
Number of subjects: 74
Study 26163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated time appointment system
Number of subjects: 354
Study 26163505 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 354
Study 23294967 — intervention group
Group type: COMPARATOR
Intervention: Staff training intervention for nurse aides (NAs) focused on offering choice during morning care for 12 weeks.
Number of subjects: 169
Study 21397541 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive approach with regular galactomannan (GM) assays and caspofungin, amphotericin or voriconazole (CAV)
Number of subjects: 52
Study 21397541 — intervention group
Group type: COMPARATOR
Intervention: Empirical approach with CAV according to established guidelines
Number of subjects: 52
Study 18978609 — intervention group
Group type: EXPERIMENTAL
Intervention: PWC V O2
Number of subjects: 10
Study 18978609 — intervention group
Group type: EXPERIMENTAL
Intervention: PWC HRT
Number of subjects: 10
Study 18978609 — intervention group
Group type: EXPERIMENTAL
Intervention: VT
Number of subjects: 10
Study 17039508 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 596
Study 17039508 — intervention group
Group type: COMPARATOR
Intervention: Standard Compression
Number of subjects: 596
Study 12902951 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc II arthroplasty
Number of subjects: 39
Study 12902951 — intervention group
Group type: COMPARATOR
Intervention: 360 degrees lumbar spinal fusion
Number of subjects: 39
Study 10858844 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(+)‐ketamine (1.5 mg/kg)
Number of subjects: 80
Study 10858844 — intervention group
Group type: COMPARATOR
Intervention: ketamine‐racemic mixture (3 mg/kg)
Number of subjects: 80
Study 9350068 — intervention group
Group type: COMPARATOR
Intervention: 20 g of n‐3 PUFA
Number of subjects: 94
Study 9350068 — intervention group
Group type: COMPARATOR
Intervention: 0.65 g of n‐3 PUFA
Number of subjects: 94
Study 9350068 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of n‐3 PUFA
Number of subjects: 94
Study 1439627 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac + 200 µg misoprostol)
Number of subjects: 346
Study 1439627 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac
Number of subjects: 346
Study 3762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid drugs
Number of subjects: 5
Study 3762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (parenterally)
Number of subjects: 5
Study 3762946 — intervention group
Group type: COMPARATOR
Intervention: Naloxone placebo
Number of subjects: 5
Study 30682359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1000 mg
Number of subjects: 183
Study 30682359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 183
Study 28039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation after partial glossectomy
Number of subjects: 62
Study 28039737 — intervention group
Group type: COMPARATOR
Intervention: Partial glossectomy
Number of subjects: 62
Study 28039737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction group
Number of subjects: 62
Study 25912040 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental soy-based formula 1 (EF1) containing scFOS (2.5 g/L) and mixed carotenoids
Number of subjects: 188
Study 25912040 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental soy-based formula 2 (EF2) containing scFOS (2.5 g/L) and mixed carotenoids
Number of subjects: 188
Study 25912040 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF) with no scFOS and no mixed carotenoids
Number of subjects: 188
Study 23771008 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim goggles (test group)
Number of subjects: 125
Study 23771008 — intervention group
Group type: COMPARATOR
Intervention: Goggles with central lens cut out (control group)
Number of subjects: 125
Study 22121934 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 40
Study 22121934 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 40
Study 19517421 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness after medical abortion (mean 14.5 mm for women who underwent D&C)
Number of subjects: 2208
Study 19517421 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness thresholds (dichotomized at 5-mm increments from 10 to 30 mm)
Number of subjects: 2208
Study 19517421 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for endometrial thickness
Number of subjects: 2208
Study 19517421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean endometrial thickness for women who did not undergo D&C (10.9 mm)
Number of subjects: 2208
Study 17923208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate topical cream
Number of subjects: 110
Study 17923208 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream (placebo)
Number of subjects: 110
Study 17923208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate topical cream (after second treatment)
Number of subjects: 110
Study 17923208 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream (placebo) (after second treatment)
Number of subjects: 110
Study 15756159 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 s rest interval group
Number of subjects: 15
Study 15756159 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 s rest interval group
Number of subjects: 15
Study 15756159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 11712401 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0
Study 11712401 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0
Study 11712401 — intervention group
Group type: COMPARATOR
Intervention: Lispro insulin
Number of subjects: 0
Study 9613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral graft
Number of subjects: 25
Study 9613385 — intervention group
Group type: COMPARATOR
Intervention: Partial tenotomy with adjuvant antimetabolite (5-fluorouracil or mitomycin C)
Number of subjects: 25
Study 8084972 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated systolic and diastolic blood pressure levels
Number of subjects: 315
Study 8084972 — intervention group
Group type: COMPARATOR
Intervention: Duration of hypertension
Number of subjects: 315
Study 3050533 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 3050533 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study 4371672 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol, dose adjusted to symptoms, for 13 to 20 months
Number of subjects: 26
Study 4371672 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 26
Study 30295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term use of zopiclone, zolpidem, or temazepam (BZDA) with psychosocial support
Number of subjects: 92
Study 30295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term use of zopiclone, zolpidem, or temazepam (BZDA)
Number of subjects: 92
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX) with leucovorin rescue
Number of subjects: 192
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dose MTX with PEG asparaginase without leucovorin rescue
Number of subjects: 192
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 192
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 192
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 10 years at diagnosis
Number of subjects: 192
Study 28671857 — intervention group
Group type: EXPERIMENTAL
Intervention: US public health insurance
Number of subjects: 192
Study 25981348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 5mg/day
Number of subjects: 119
Study 25981348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 10mg/day
Number of subjects: 119
Study 25981348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 20mg/day
Number of subjects: 119
Study 25981348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 23876953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass technique
Number of subjects: 30
Study 23876953 — intervention group
Group type: COMPARATOR
Intervention: Scrubbing technique
Number of subjects: 30
Study 23876953 — intervention group
Group type: COMPARATOR
Intervention: Modified Stillman technique
Number of subjects: 30
Study 21857142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5-5 mg/day)
Number of subjects: 75
Study 21857142 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (20-40 mg/day)
Number of subjects: 75
Study 21857142 — intervention group
Group type: COMPARATOR
Intervention: Switching from fluvastatin to rosuvastatin
Number of subjects: 75
Study 19216014 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused atorvastatin therapy
Number of subjects: 2442
Study 19216014 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2442
Study 17926823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + Methotrexate
Number of subjects: 1150
Study 17926823 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 1150
Study 17926823 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 1150
Study 17926823 — intervention group
Group type: COMPARATOR
Intervention: Rituximab + Steroid
Number of subjects: 1150
Study 14716774 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-continuous group (3 MU of IFN-alpha three times weekly for 24 months)
Number of subjects: 30
Study 14716774 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-intermittent group (3 MU of IFN-alpha daily for 10 days every month for 6 months, then 3 MU daily for 10 days every 3 months for 18 months)
Number of subjects: 30
Study 14716774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN-alpha therapy)
Number of subjects: 30
Study 11246548 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 58
Study 11246548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil diet
Number of subjects: 58
Study 11246548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet
Number of subjects: 58
Study 11246548 — intervention group
Group type: COMPARATOR
Intervention: Wash-in diet rich in saturated fatty acids
Number of subjects: 58
Study 9218075 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 750 mg b.d.
Number of subjects: 381
Study 9218075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus amoxycillin 750 mg b.d.
Number of subjects: 381
Study 8128835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA), a cholinesterase inhibitor, chronic dose
Number of subjects: 89
Study 8128835 — intervention group
Group type: COMPARATOR
Intervention: Nicotine, acute dose
Number of subjects: 89
Study 3278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystoenterostomy
Number of subjects: 31
Study 3278638 — intervention group
Group type: COMPARATOR
Intervention: Choledochoenterostomy
Number of subjects: 31
Study 3278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystoenterostomy (in malignant biliary obstruction subgroup)
Number of subjects: 31
Study 30926400 — intervention group
Group type: EXPERIMENTAL
Intervention: ReHand tablet application (experimental group)
Number of subjects: 50
Study 30926400 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program on paper (control group)
Number of subjects: 50